JUVÉDERM ULTRA PLUS XC 1 mL, 2syr (SHIPS TO MEDICAL OFFICE ONLY)

PLEASE ADVISE: Allergan requires a medical office to ship to. Please email inventory@hydrieght.com with this information to submit for approval before ordering. 

A robust, 20% thicker HA gel, ideal for volumizing more severe facial folds.

2 Syringes Per Box

Composition:

• 24 mg/mL of cross-linked hyaluronic acid gel formulated with 0.3% lidocaine, in phosphate buffer, at a neutral pH.

 Treatment Areas:

• Volumizing and correcting deeper folds and wrinkles, eg, nasolabial folds, oral commissures, and marionettes.

Indication: In the United States, JUVÉDERM^® injectable gel (including JUVÉDERM^® Ultra, JUVÉDERM^® Ultra Plus, JUVÉDERM^® Ultra XC, and JUVÉDERM^® Ultra Plus XC) is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

Contraindications: JUVÉDERM^® injectable gel should not be used in patients who have severe allergies marked by a history of anaphylaxis or history or presence of multiple severe allergies. JUVÉDERM^® should not be used in patients with a history of allergies to Gram-positive bacterial proteins. JUVÉDERM^® Ultra XC and JUVÉDERM^® Ultra Plus XC should not be used in patients with a history of allergies to lidocaine.

Warnings: JUVÉDERM^® injectable gel should not be injected into blood vessels. If there is an active inflammatory process or infection at specific injection sites, treatment should be deferred until the underlying process is controlled. Precautions: The safety of JUVÉDERM^® for use during pregnancy, in breastfeeding females, or in patients under 18 years has not been established. The safety and effectiveness of JUVÉDERM^® injectable gel for the treatment of areas other than facial wrinkles and folds (such as lips) have not been established in controlled clinical studies. Patients who are using substances that can prolong bleeding, such as aspirin or ibuprofen, as with any injection, may experience increased bruising or bleeding at injection site. Patients should inform their physician before treatment if they are using these types of substances. As with all skin-injection procedures, there is a risk of infection. JUVÉDERM^® should be used with caution in patients on immunosuppressive therapy, or therapy used to decrease the body’s immune response, as there may be an increased risk of infection. The safety of JUVÉDERM^® in patients with a history of excessive scarring (eg, hypertrophic scarring and keloid formations) and pigmentation disorders has not been studied. If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment with JUVÉDERM^® injectable gel, or if JUVÉDERM^® is administered before the skin has healed completely after such a